New England Research & Management Inc. cut its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 10.8% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,660 shares of the biopharmaceutical company’s stock after selling 200 shares during the quarter. New England Research & Management Inc.’s holdings in Regeneron Pharmaceuticals were worth $927,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
A number of other hedge funds and other institutional investors have also recently bought and sold shares of REGN. Ironwood Wealth Management LLC. lifted its stake in Regeneron Pharmaceuticals by 17.5% in the 4th quarter. Ironwood Wealth Management LLC. now owns 235 shares of the biopharmaceutical company’s stock worth $114,000 after purchasing an additional 35 shares in the last quarter. Armistice Capital LLC lifted its stake in Regeneron Pharmaceuticals by 57.1% in the 4th quarter. Armistice Capital LLC now owns 132,000 shares of the biopharmaceutical company’s stock worth $63,771,000 after purchasing an additional 48,000 shares in the last quarter. Cetera Investment Advisers bought a new position in shares of Regeneron Pharmaceuticals in the 4th quarter worth $1,100,000. Canada Pension Plan Investment Board increased its holdings in shares of Regeneron Pharmaceuticals by 24.1% in the 4th quarter. Canada Pension Plan Investment Board now owns 6,692 shares of the biopharmaceutical company’s stock worth $3,233,000 after buying an additional 1,301 shares during the last quarter. Finally, United Capital Financial Advisers LLC increased its holdings in shares of Regeneron Pharmaceuticals by 13.4% in the 4th quarter. United Capital Financial Advisers LLC now owns 2,372 shares of the biopharmaceutical company’s stock worth $1,146,000 after buying an additional 281 shares during the last quarter. Institutional investors and hedge funds own 82.90% of the company’s stock.
Shares of Regeneron Pharmaceuticals stock opened at $574.61 on Monday. The company has a market cap of $61.22 billion, a price-to-earnings ratio of 16.26, a PEG ratio of 0.55 and a beta of 0.15. Regeneron Pharmaceuticals, Inc. has a 12-month low of $441.00 and a 12-month high of $660.00. The company has a debt-to-equity ratio of 0.17, a quick ratio of 2.45 and a current ratio of 3.12. The stock has a fifty day moving average price of $548.37.
Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its earnings results on Thursday, May 6th. The biopharmaceutical company reported $9.89 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $7.78 by $2.11. Regeneron Pharmaceuticals had a net margin of 43.53% and a return on equity of 35.43%. The firm had revenue of $2.53 billion during the quarter, compared to analysts’ expectations of $2.69 billion. During the same period last year, the company posted $6.60 EPS. The company’s quarterly revenue was up 38.3% compared to the same quarter last year. As a group, sell-side analysts expect that Regeneron Pharmaceuticals, Inc. will post 46.64 earnings per share for the current year.
A number of equities analysts have recently commented on REGN shares. Royal Bank of Canada increased their price target on shares of Regeneron Pharmaceuticals from $629.00 to $679.00 and gave the stock a “sector perform” rating in a report on Friday, July 23rd. Robert W. Baird reissued a “hold” rating on shares of Regeneron Pharmaceuticals in a report on Tuesday, April 13th. SVB Leerink decreased their price target on shares of Regeneron Pharmaceuticals from $657.00 to $641.00 and set an “outperform” rating on the stock in a report on Friday, May 7th. HC Wainwright reissued a “buy” rating and issued a $741.00 price target (up previously from $729.00) on shares of Regeneron Pharmaceuticals in a report on Monday. Finally, Morgan Stanley increased their target price on shares of Regeneron Pharmaceuticals from $477.00 to $495.00 and gave the company an “equal weight” rating in a report on Friday, May 7th. Five investment analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company’s stock. Regeneron Pharmaceuticals currently has a consensus rating of “Buy” and a consensus target price of $657.00.
In other news, EVP Joseph J. Larosa sold 3,398 shares of Regeneron Pharmaceuticals stock in a transaction that occurred on Tuesday, July 6th. The shares were sold at an average price of $580.00, for a total value of $1,970,840.00. Following the completion of the sale, the executive vice president now directly owns 23,182 shares in the company, valued at $13,445,560. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Marion Mccourt sold 1,000 shares of Regeneron Pharmaceuticals stock in a transaction that occurred on Friday, May 7th. The stock was sold at an average price of $495.63, for a total transaction of $495,630.00. Following the completion of the sale, the executive vice president now owns 18,038 shares of the company’s stock, valued at $8,940,173.94. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 86,682 shares of company stock valued at $46,831,512. Corporate insiders own 10.76% of the company’s stock.
About Regeneron Pharmaceuticals
Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.
Read More: Options Trading – Understanding Strike Price